Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TVG's LSDV vaccine is a herpesvirus-based viral-vector vaccine designed to protect cattle against Lumpy Skin Disease Virus (LSDV). Developed by The Vaccine Group (TVG), the vaccine utilizes a proprietary herpesvirus vector platform to express LSDV antigens, aiming to induce protective immunity. Preclinical studies have demonstrated immunogenicity in calves. This approach leverages the ability of herpesviruses to induce robust and long-lasting immune responses in livestock, potentially offering a more effective alternative to traditional live-attenuated vaccines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LSDV vaccine.